IONS vs KYMR โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
KYMR Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Kymera Therapeutics, Inc. Common Stock (KYMR) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while IONS counters with relative strength in Valuation. Fundamentally, IONS trades at 90.9x Forward P/E with -58.8% operating margin (+54.9% YoY revenue) versus KYMR at N/M Forward P/E and -396.0% operating margin (+466.4% YoY). In options structure, IONS sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro) against KYMR sits in CONSOLIDATION (23rd %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | IONS Revenue | KYMR Revenue | IONS Op. Margin | KYMR Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $600M | N/A | -10.2% | N/A | IONS |
| FY2019 | $1.12B | $0M | 32.6% | -1438.5% | IONS |
| FY2020 | $730M | $30M | -23.6% | -136.1% | IONS |
| FY2021 | $810M | $70M | -3.7% | -138.0% | IONS |
| FY2022 | $590M | $50M | -69.8% | -344.4% | IONS |
| FY2023 | $790M | $80M | -44.9% | -210.6% | IONS |
| FY2024 | $710M | $50M | -67.4% | -555.8% | IONS |
| FY2025 | $940M | $40M | -40.4% | -891.1% | IONS |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | IONS | KYMR | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $4.7B | $10.9B | Larger Scale | KYMR |
| Trailing P/E Ratio Valuation | 90.9x | N/M | Lower Multiple | IONS |
| Forward P/E Ratio Valuation | 90.9x | N/M | Lower Multiple | IONS |
| Revenue Growth (YoY) Growth | +54.9% | +466.4% | Higher Growth | KYMR |
| Operating Margin (TTM) Profitability | -58.8% | -396.0% | Higher Margin | IONS |
| Net Profit Margin Profitability | -56.9% | 0.0% | Higher Margin | KYMR |
| Return on Equity (ROE) Capital Efficiency | -108.0% | -27.3% | Higher ROE | KYMR |
| 52-Week Range Position Momentum | 2% ($27โ$87) | 78% ($62โ$143) | Stronger Trend | KYMR |
| Beta / 30D Volatility Risk Regime | 0.18ฮฒ ยท 86% Vol | 1.04ฮฒ ยท 54% Vol | Lower Realized Risk | KYMR |
| Unified Institutional Score Composite Signal | 63.9 / 100 (BUY) | 47.1 / 100 (HOLD) | Higher Composite | IONS |